35000 Participants Needed

Registry Study for Huntington's Disease

Recruiting at 177 trial locations
EN
NM
Overseen ByNoopur Modi
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: CHDI Foundation, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is a long-term, observational study focused on Huntington's disease (HD). It aims to gather detailed data to help researchers understand disease progression and identify key markers for future treatments. The study includes individuals who either carry the gene for HD, have relatives with HD, or do not carry the gene as a control group. Those with HD symptoms or relatives with HD might be suitable for this trial. Researchers may update participants' genetic status based on findings, but this information will remain unknown to them and their doctors during the study. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to new insights and treatments for Huntington's disease.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to gather comprehensive data on Huntington's Disease (HD) by observing a global cohort. Unlike standard treatments that focus on managing symptoms, this observational study seeks to understand the disease's progression and genetic factors better. By collecting and analyzing data over time, the study hopes to uncover new insights that could lead to more effective therapies and improve the quality of life for those with HD. This approach could pave the way for breakthroughs in how we understand and tackle Huntington's Disease in the future.

Who Is on the Research Team?

BG

Bernhard G Landwehrmeyer, MD, PhD

Principal Investigator

University of Ulm

JL

Jamie Levey

Principal Investigator

CHDI Foundation, Inc.

Are You a Good Fit for This Trial?

Inclusion Criteria

Carriers: This group comprises the primary study population and consists of individuals who carry the HD gene expansion mutation.
Controls: This group comprises the comparator study population and consists of individuals who do not carry the HD expansion mutation.
Genotype Negative: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has undergone predictive testing for HD and is known not to carry the HD expansion mutation.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Enrollment and Baseline Assessment

Participants are enrolled and baseline assessments are conducted, including cognitive, motor, functional, and behavioral assessments

1 year
Annual assessments

Longitudinal Data Collection

Ongoing collection of clinical data and biospecimens to develop a comprehensive repository for HD research

Long-term
Annual assessments

Follow-up

Participants are monitored for safety and effectiveness after initial assessments

1 year

What Are the Treatments Tested in This Trial?

Interventions

  • Observational Study

Find a Clinic Near You

Who Is Running the Clinical Trial?

CHDI Foundation, Inc.

Lead Sponsor

Trials
17
Recruited
39,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security